LH earnings call for the period ending June 30, 2020.
News & Analysis: Laboratory Corporation of America
COVID-19 hurt the life sciences company in the second quarter. But it also helped.
The diagnostics industry leader's PhenoSense assay will also gauge how well a patient's antibodies will fare in fighting off SAR-CoV-2.
The coronavirus pandemic is having a big impact on LabCorp, but maybe not in the way you expected.
Companies will be able to screen their employees for the coronavirus and test them for prior infections with SARS-CoV-2.
It's a really close contest between these two diagnostics-testing stocks.
LH earnings call for the period ending March 31, 2020.
The company got off to a strong start in the first quarter but saw a big drop in diagnostic testing in the last two weeks of the quarter due to the coronavirus outbreak.
With supplies currently limited, kits will be prioritized for healthcare workers and first responders, but as production ramps up in coming weeks, they will be made broadly available.
Diagnostic laboratories, rather than the test manufacturers, may be the biggest beneficiaries.